Drug intelligence / Profile preview

ZENFluxion

Development stage: Unknown
Lead developer: Zylox-Tonbridge
Modality: Small Molecules, Device-based Delivery → Drug Delivery Systems
Administration: Percutaneous

Overview

ZENFluxion is a paclitaxel-coated balloon catheter medical device developed by Zylox-Tonbridge Medical Technology (also known as Zylox Medical). It is designed for Percutaneous Transluminal Angioplasty (PTA) to treat stenotic or occlusive lesions in the iliac, femoral, and popliteal arteries, primarily for the management of Peripheral Artery Disease (PAD). The device utilizes a specialized microcrystal layer to deliver paclitaxel directly to the vessel wall, where it acts as an anti-proliferative agent to prevent restenosis by inhibiting neointimal hyperplasia. ZENFluxion has received marketing approval in China (NMPA), the European Union (CE Mark), and the United Arab Emirates.

Brand names: ZENFluxion

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ZENFluxion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZENFluxion.

Explore the full profile